NuvOx
NUOXNuvOx Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative oxygen therapeutic solutions to treat diseases characterized by hypoxia.
NuvOx has filed an S-1 registration statement with the SEC and is not yet trading. Financial statements will appear here once it begins reporting as a public company.
S-1 Filings
Registration statements filed with the SEC ahead of the planned listing
Competitors
By market cap
By revenue growth
Profile
NuvOx Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative oxygen therapeutic solutions to treat diseases characterized by hypoxia. Its core technology utilizes a proprietary perfluorocarbon emulsion that facilitates oxygen transfer from red blood cells to tissues, addressing unmet medical needs in oncology, neurology, and respiratory care.
NuvOx is a pioneer in nano-sized oxygen carriers, holding orphan drug designations and advancing multiple Phase IIb trials for high-mortality conditions.
Questions, answered.
- Who are NuvOx's competitors?
- NuvOx's key competitors include Novocure, Oragenics Inc., Inogen Inc, and others. These companies compete in similar markets and product categories.
- Who does NuvOx partner with?
- NuvOx's notable partners include FluoroMed, L.P., University of Arkansas, University of Glasgow, and others.
- Where is NuvOx headquartered?
- NuvOx is headquartered in United States of America.